Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico
ConclusionAccounting for model uncertainty, rFVIIa provided cost savings over pd-aPCC for the Mexican public health care payer in the management of mild-to-moderate joint bleeds in pediatric hemophilia A with inhibitors.
Source: Value in Health Regional Issues - Category: International Medicine & Public Health Source Type: research
More News: Children | Haemophilia | Health Management | Hemophilia | International Medicine & Public Health | Mexico Health | Pediatrics